Armata Pharmaceuticals (ARMP) Total Current Liabilities (2013 - 2026)

Armata Pharmaceuticals has disclosed Total Current Liabilities across 14 years of filings, most recently posting $9.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $9.2 million, down 91.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.2 million (down 91.65% YoY), and the FY2025 annual result was $8.9 million, down 81.46% from the prior year.
• Total Current Liabilities came in at $9.2 million for Q1 2026 at Armata Pharmaceuticals, up from $8.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $140.0 million in Q3 2025 to a low of $6.2 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $48.2 million (2024), against an average of $57.4 million.
• Across the five-year window, Total Current Liabilities soared 725.81% in 2023 and slumped 91.65% in 2026, its largest moves.
• Armata Pharmaceuticals' Total Current Liabilities stood at $24.9 million in 2022, then tumbled by 33.82% to $16.5 million in 2023, then surged by 193.11% to $48.2 million in 2024, then slumped by 81.46% to $8.9 million in 2025, then grew by 3.14% to $9.2 million in 2026.
• The last three Total Current Liabilities figures came in at $9.2 million (Q1 2026), $8.9 million (Q4 2025), and $140.0 million (Q3 2025), per Business Quant data.